A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

NCT07258979 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

202

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent or Metastatic Nasopharyngeal Carcinoma

Interventions

DRUG: YL201
DRUG: Toripalimab
DRUG: Cisplatin

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.